Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs.

Breast cancer research : BCR - 15 May 2020

Reddy Tejaswini P, Choi Dong S, Anselme Ann C, Qian Wei, Chen Wen, Lantto Johan, Horak Ivan D, Kragh Michael, Chang Jenny C, Rosato Roberto R

Abstract excerpt

BACKGROUND: The human epidermal growth factor receptor (HER) family, notably EGFR, is overexpressed in most triple-negative breast cancer (TNBC) cases and provides cancer cells with compensatory signals that greatly contribute to the survival and development of resistance in response to therapy. This study investigated the effects of Pan-HER (Symphogen, Ballerup, Denmark), a novel mixture of six monoclonal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Molecular Targeted Therapy

Share to Receptor, ErbB-2

Share to Receptor, ErbB-3

Share to Triple Negative Breast Neoplasms

Share to Tumor Cells, Cultured

Source

Open in PubMed Open full text

Identifiers

PMID: 32414394
DOI: 10.1186/s13058-020-01280-z
PMCID: PMC7227035

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs.PMID 32414394Read ↗

Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and PlasticitySemantic proximity Read ↗

Therapeutic targeting of the epidermal growth factor receptor in human cancer.Semantic proximity Read ↗

Novel antibody cocktail therapy targeting extracellular tumor-specific mutations to treat triple-negative breast cancerSemantic proximity Read ↗

Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR familySemantic proximity Read ↗

Engineered bivalent ligands to bias ErbB receptor-mediated signaling and phenotypes.Semantic proximity Read ↗

Novel antibody cocktail therapy targeting extracellular tumor-specific mutations to treat EMT6 cell line-derived triple-negative breast cancer.Semantic proximity Read ↗

A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor ResponseSemantic proximity Read ↗

Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes.Semantic proximity Read ↗

Inhibition of HER Receptors Reveals Distinct Mechanisms of Compensatory Upregulation of Other HER Family Members: Basis for Acquired Resistance and for Combination TherapySemantic proximity Read ↗

Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapySemantic proximity Read ↗

Targeting HER3 for cancer treatment: a new horizon for an old targetSemantic proximity Read ↗

HER kinase inhibition in patients with HER2- and HER3-mutant cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.